风投脉搏——2017年Q1全球风险投资分析报告（英文版）_124页_2mb

Venture Pulse Q1 2017 Summary

Core Content

This document provides a global analysis of venture capital (VC) investment trends in the first quarter of 2017, highlighting the shifts in deal volume, deal size, and investor behavior across different regions and sectors.

Main Points

Global Trends

• Activity Decline: Venture capital activity decreased for the fourth consecutive quarter, from 3,201 completed financings in Q4 2016 to 2,716 in Q1 2017, a drop of 15.2%.
• Capital Plateau: Despite the decline in deal volume, total capital invested reached a new plateau, with $23.8 billion in Q4 2016 and nearly $27 billion in Q1 2017.
• Investor Caution: The decrease in deal volume suggests investors are more cautious, but the availability of dry powder remains high.

Americas

• Decline in Deal Volume: The Americas experienced a continued decline in total deal volume, extending a trend that began in Q2 2015.
• Canada: VC investment in Canada dropped in Q1 2017 but may benefit from recent government support.
• Latin America: Mexican VC investment dropped significantly due to uncertainty around potential US policy changes. Brazil saw solid investment, notably from 99Taxis.
• US Focus on International Opportunities: US investors showed increased interest in international VC opportunities, especially in Europe and Latin America, due to exchange rate fluctuations and higher ROI potential.

Europe

• Seed and Angel Rounds Decline: Deal volume for seed and angel rounds continued to decline, with corporate VC participation reaching a 7-year high at 22%.
• Large Fundraising: European VC Atomico raised a $765 million fund, reflecting a trend toward fewer but larger VC funds.
• Medtech Dominance: Medtech attracted significant VC interest, particularly in the US, Israel, and Canada. Companies like Grail and MedLumics saw major funding rounds.

Asia

• Slow Start to 2017: After a record year in 2016, Asia saw a slow start in Q1 2017, with the lowest number of completed financings since 2012.
• IPO Challenges: The US IPO market showed signs of recovery with the success of Snap, Mulesoft, and Alteryx, which could influence global VC activity.
• Chinese Cautiousness: Chinese investors remained cautious, influenced by economic concerns and regulatory barriers, though some outbound investment still occurred.

Sectors and Trends

• Medtech as a Key Sector: Medtech remained a dominant area for VC investment, with continued interest in subsectors like orthopedics, imaging, diagnostics, and cardiology.
• Corporate VC Growth: Corporate VC participation reached an all-time high of 17% globally, driven by strategic interests and the need for innovation.
• First-Time Financings: The number of first-time financings declined, but the total VC invested in these rounds remained stable, indicating a shift toward more selective investment.
• Unicorn Activity: The unicorn phenomenon peaked in 2015 and declined since, though there was a mild uptick in Q1 2017 with 14 unicorn rounds.

Key Information

Deal Metrics

• Median Deal Sizes:
  • Series A: $5.7 million
  • Series B: $14 million
  • Series C: $22 million (down from $23 million in Q4 2016)
  • Series D or later: Median pre-money valuation dropped from $180.5 million to $155 million.

Regional Highlights

• US:
  • 497 first-time financings totaling $1.6 billion.
  • CVC participation reached 17% of all deals.
  • Medtech and other sectors saw significant investment.
• Europe:
  • Corporate VC participation at 22%.
  • Seed and angel rounds declined, but large VC funds were raised.
• Asia:
  • Overall investment dropped to the lowest quarterly level since 2012.
  • Chinese investors remained cautious, with regulatory hurdles affecting IPO exits.

Outlook

• Market Normalization: The global VC market is expected to normalize, with activity likely to remain steady but not return to 2015 levels.
• Policy Impacts: US trade, tax, and immigration policies, along with the Brexit process, will significantly impact VC investment trends.
• IPO Market: The performance of tech IPOs in the US will influence the global VC market, especially in terms of releasing dry powder.

Summary

The Q1 2017 venture capital market showed a decline in deal volume globally, but total capital invested remained relatively high due to a few outlier deals. The Americas saw a continued decline in deal volume, while Europe and the US experienced notable shifts in investment patterns, with corporate VC participation reaching an all-time high. Medtech emerged as a key sector, with significant investment in subsectors like orthopedics and diagnostics. Despite a decline in seed and angel rounds, early-stage opportunities still attracted capital, albeit with more rigorous evaluation. The US IPO market showed signs of recovery, which could influence global VC investment. Overall, the market is expected to normalize, with a focus on quality and strategic investments.